484 related articles for article (PubMed ID: 26536664)
1. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
3. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
[TBL] [Abstract][Full Text] [Related]
4. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
[TBL] [Abstract][Full Text] [Related]
6.
Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
8. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
10. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
11. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
[TBL] [Abstract][Full Text] [Related]
12. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
13. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
14. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
15. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
16. A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
Kobayashi K; Sasaki T; Takenaka F; Yakushiji H; Fujii Y; Kishi Y; Kita S; Shen L; Kumon H; Matsuura E
J Immunol Res; 2015; 2015():268172. PubMed ID: 25883990
[TBL] [Abstract][Full Text] [Related]
17. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
[TBL] [Abstract][Full Text] [Related]
18. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
[TBL] [Abstract][Full Text] [Related]
19. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
20. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
Alsaid H; Skedzielewski T; Rambo MV; Hunsinger K; Hoang B; Fieles W; Long ER; Tunstead J; Vugts DJ; Cleveland M; Clarke N; Matheny C; Jucker BM
PLoS One; 2017; 12(4):e0176075. PubMed ID: 28448604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
